The National Gene Vector Biorepository (NGVB) at Indiana University provides essential resources for academic institutions and organizations engaged in clinical gene therapy research. One of the key offerings is their testing services, which assist eligible investigators in meeting FDA requirements for clinical gene therapy under Good Manufacturing Practice (GMP). This ensures that the therapies developed are safe and effective for clinical use. Additionally, the NGVB offers archiving services, where samples are stored under Good Laboratory Practice (GLP) or Good Clinical Practice (GCP) conditions at no cost, further supporting researchers in compliance with FDA guidelines.

Moreover, the NGVB maintains a comprehensive repository of over 80 reagents, including adeno-associated virus (AAV) and lentiviral vector plasmids, certified cell lines, and retroviral packaging cell lines. This extensive collection of reagents is crucial for researchers developing gene therapies, providing them with the necessary tools to advance their studies. The NGVB's commitment to supporting clinical gene therapy research is reinforced by its funding from the National Heart, Lung, and Blood Institute, ensuring that researchers have access to high-quality resources and services that adhere to regulatory standards.

United States

National Gene Vector Biorepository (NGVB) at Indiana University

Indiana

Adeno-associated viral vector (AAV)

Biologics

Biostorage/Biorepositories

Cell Therapies

Gene Therapy

Lentiviral Vector (LVV)

Vendor

National Gene Vector Biorepository (NGVB) at Indiana University

Company Details